Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie W Lees

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
Frontline Gastroenterology|June 21, 2024
Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort studyAlexander Thomas Elford, Maria Bishara, Nikolas Plevris, et al.
Therapeutic Advances in Gastroenterology|February 14, 2022
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studiesCharlie W Lees, J Jasper Deuring, Michael Chiorean, et al.
Gut|May 5, 2022
Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severityCharlie W Lees, Tariq Ahmad, Christopher Andrew Lamb, et al.
Frontline Gastroenterology|March 6, 2020
Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel diseaseNikolas Plevris, Philip W Jenkinson, Cher S Chuah, et al.
Journal of Crohn'S & Colitis|December 9, 2023
Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative ColitisBeatriz Gros, Mairi Goodall, Nik Plevris, et al.
Journal of Crohn'S & Colitis|December 11, 2024
Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted ComparisonBeatriz Gros, Nathan Constantine-Cooke, Jake Kennedy, et al.
Therapeutic Advances in Gastroenterology|November 11, 2024
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trialsCharlie W Lees, Joana Torres, Yvette Leung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 2, 2023
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's DiseaseNathan Constantine-Cooke, Karla Monterrubio-Gómez, Nikolas Plevris, et al.
United European Gastroenterology Journal|February 21, 2023
Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohortBeatriz Gros, Nikolas Plevris, Nathan Constantine-Cooke, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|December 22, 2020
Analysis of colectomy rates for ulcerative colitis in pre- and postbiological eras in Lothian, ScotlandPhilip W Jenkinson, Nikolas Plevris, Mathew Lyons, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
Frontline Gastroenterology|June 21, 2024
Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort studyAlexander Thomas Elford, Maria Bishara, Nikolas Plevris, et al.
Therapeutic Advances in Gastroenterology|February 14, 2022
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studiesCharlie W Lees, J Jasper Deuring, Michael Chiorean, et al.
Gut|May 5, 2022
Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severityCharlie W Lees, Tariq Ahmad, Christopher Andrew Lamb, et al.
Frontline Gastroenterology|March 6, 2020
Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel diseaseNikolas Plevris, Philip W Jenkinson, Cher S Chuah, et al.
Journal of Crohn'S & Colitis|December 9, 2023
Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative ColitisBeatriz Gros, Mairi Goodall, Nik Plevris, et al.
Journal of Crohn'S & Colitis|December 11, 2024
Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted ComparisonBeatriz Gros, Nathan Constantine-Cooke, Jake Kennedy, et al.
Therapeutic Advances in Gastroenterology|November 11, 2024
Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trialsCharlie W Lees, Joana Torres, Yvette Leung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 2, 2023
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's DiseaseNathan Constantine-Cooke, Karla Monterrubio-Gómez, Nikolas Plevris, et al.
United European Gastroenterology Journal|February 21, 2023
Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohortBeatriz Gros, Nikolas Plevris, Nathan Constantine-Cooke, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|December 22, 2020
Analysis of colectomy rates for ulcerative colitis in pre- and postbiological eras in Lothian, ScotlandPhilip W Jenkinson, Nikolas Plevris, Mathew Lyons, et al.
Pageof 10